Indian Drug Safety Crisis: Children’s Deaths Trigger Urgent Review After Toxic Cough Syrups Found

The crisis unfolds

In early October 2025, health authorities in the central Indian state of Madhya Pradesh reported a disturbing spike in acute kidney-failure cases among children under the age of five. After clinical investigation, the common link emerged as a locally-manufactured cough syrup marketed for infants and toddlers. Laboratory tests revealed that the syrup—sold under the brand name COLDRIF—contained dangerously high levels of diethylene glycol (DEG), an industrial solvent and known toxic substance. The measured quantity was nearly 500 times the permissible limit.

The death toll rose rapidly: at least 17 children had died by early October, and by mid-month other reports indicated 20 or more fatalities in linked incidents. Investigations extended to other cough-syrup brands—including Respifresh TR and ReLife—both produced by firms in the pharmaceutical‐hub state of Gujarat, which were found in preliminary testing to also contain DEG, although no deaths were formally linked to them so far.

Regulatory response and institutional accountability

The CDSCO quickly issued a formal alert and directed state regulators to halt production, suspend product‐authorisations and recall affected batches. In parallel, the WHO issued Medical Product Alert No. 5/2025 on 13 October identifying three contaminated oral liquid medicines in India. The Indian government also refused a pharma‐industry plea to extend the deadline for manufacturing-facility upgrades to international standards, signalling stricter enforcement ahead.

Despite these steps, a broader and more alarming issue surfaced: the WHO highlighted a **regulatory gap** in India whereby drugs meant for export are subject to contaminant-testing, but those sold domestically are not necessarily so. “They have made some strides,” said WHO official Rutendo Kuwana. “But enforcement issues persist.”

Why this matters: India’s pharmaceutical sector under scrutiny

India is the world’s third-largest producer of medicines by volume, supplying generics and finished formulations globally. Still, these recent events underscore that domestic regulatory and quality-control systems may be weaker than for export markets. The presence of DEG contamination is not new—it has previously resulted in child-fatalities in India and abroad from syrups made in India or Indonesia.

For Indian public health, this incident is a major credibility challenge. Beyond the immediate tragedy of lost lives, it raises questions about manufacturing standards, supply-chain oversight, regulatory inspections, and corporate accountability. Hospitals and paediatric intensive-care units in the affected regions faced pressure, as doctors scrambled to treat acute renal toxicities that are regrettably irreversible in many cases. Families suffered unimaginable loss.

Root-cause analysis: What went wrong?

Pharma-engineering experts and regulators have pointed to multiple contributory failures:

• Manufacturing control weak-spots: The DEG contamination arises when industrial-grade glycol substitutes are used (or inadvertently introduced) in place of pharmaceutical‐grade humectants like glycerin. In the Coldrif case, the reported 48.6 % DEG reading points to catastrophic breakdown in safety systems.
• Quality testing mismatch: While export-market consignments undergo rigorous contaminant-screening, domestically-sold syrups were apparently exempt from equivalent checks—or the systems were insufficient. The WHO flagged this.
• Traceability and batch-control gaps: The recall process depends on supply-chain trace-back; here, mapping of batches, distribution chains and informal sales channels may have had gaps. Experts warned that rural and informal pharmacies could continue supplying unsafe stock.
• Regulatory enforcement capacity: Multiple manufacturing sites may lack updated infrastructure; the government is now mandating upgrades but the backlog is large.

Impact: On children, families, and public trust

The human cost is devastating. The affected children were aged under five, many presented with acute dehydration, followed by kidney‐failure and multi‐organ malfunction. Parents who trusted a common cough-syrup found themselves in hospital corridors, awaiting death or long-term dialysis. The emotional trauma, long-term disability burden and economic cost are enormous.

Beyond individual families, there is a systemic trust deficit surfacing: in rural and small-town India, where informal pharmacies and local clinicians are common, patients expect safety assurances. When that fails, health-system credibility suffers. The pharma industry, which once enjoyed pride in India’s generics leadership, now faces fresh reputational risk.

Wider health policy context and implications

This incident occurs against a backdrop of growing non-communicable disease (NCD) burden, rising healthcare costs and shifting demographic pressure. India must ensure that its pharmaceutical system keeps pace with safety expectations. For example, a recent analysis projects India could lose USD 4.58 trillion by 2030 due to NCDs and mental‐health conditions.

The recall and oversight failure also place a spotlight on medicine affordability, access and regulation. Health-economics frameworks emphasise that no country achieves health-security without strong regulatory architecture. This episode may become a turning point—if lessons are learned and systems strengthened.

Next-steps: What must change

To restore safety, credibility and trust, several action-areas are now urgent:

1. Immediate: thorough audit of all paediatric syrups – national regulators must test every batch of cough and cold syrups marketed domestically for traditional toxins like DEG and ethylene glycol, and mandate recalls where found.
2. Facility upgrades & licencing overhaul: All manufacturers supplying paediatric liquids should be certified to global GMP (Good-Manufacturing Practice) standards, undergo annual unannounced inspections and face criminal penalties for violations.
3. Supply-chain traceability & enforcement: Distribution tracing, banning of informal channels, digital batch tracking and transparent recalls must be implemented. Informal pharmacies and rural supply networks are potential weak links.
4. Regulatory harmonisation domestic/export markets: India must ensure domestic formulations meet the same contaminant-testing standards as exports; the WHO flagged this disparity.
5. Public communication & trust-building: Affected families need transparent information, support, compensation frameworks, and improved grievance redress mechanisms. Trust-redeeming actions are essential.
6. Longer-term investing in regulatory capacity: Expand national laboratory networks, strengthen state-level enforcement, build digital databases and integrate health-safety oversight as part of health-system strengthening. The EY health-care paper highlighted this need.

International angle & export implications

Although the controversial syrups were sold domestically and not exported, the incident triggers global regulatory concern. The U.S. Food and Drug Administration (FDA) confirmed that the contaminated syrups were **not** shipped to the U.S. but continues to watch for leakage.  Other countries often rely on Indian generics; hence India’s global pharma reputation is at stake.

The lesson for India’s positioning in global medicine supply-chains is clear: safety cannot be assumed, and regulatory lapses affect credibility, trade, investment and public health diplomacy.

Conclusion: Crisis as catalyst for reform

The death of innocent children from a supposedly harmless cough-syrup is a stark reminder of the stakes involved in medicine regulation. India’s health-care miracle story—cheap generics for the world, domestic access improvement—must now include robust regulatory pride. The scars of this incident will remain unless systemic reform follows.

For patients, parents and health-professionals, the immediate demand is clear: safe medicines, transparent regulation and accountability. For the government and industry, the message is no less urgent: cut costs, but not corners; grow scale, but not at the expense of safety; lead the world in access—but only if you guarantee quality. India’s next chapter in health-care depends not just on innovation and scale, but on trust and integrity.